38
nanotimes
Companies Facts
P
hotronics, Inc. (NASDAQ: PLAB) paid approxi- mately $35 million to Micron Technology, Inc.
in connection with the purchase of its US nanoFab building in Boise, ID that it previously leased from the building’s owner Micron. In connection there- with, the Company also amended its credit facility adding a 5-year term loan for $25 million and redu- cing interest rates by 25 basis points on borrowings as defined in the credit facility.
Photronics is a leading worldwide manufacturer of photomasks.
http://www.photronics.com p
Sivida Corp. (NASDAQ: PSDV) announced the positive outcome of the Decentralized Procedure (DCP) for the approval of ILUVIEN®
in Europe. The
regulatory process will now enter the national phase of the DCP in which the RMS and each CMS grants its national license. The CMS include Austria, France, Germany, Italy, Portugal and Spain. ILUVIEN will be indicated for the treatment of vision impairment as- sociated with chronic DME considered insufficiently responsive to available therapies.
pSivida has also entered into a technology evalua- tion agreement for its bioerodible Durasert™ drug delivery technology in ophthalmology with Neuron Systems, Inc., an ocular drug development company based in Burlington, USA. Under this agreement, the companies will evaluate the use of pSivida’s techno- logy as a delivery system for a treatment for dry age related macular degeneration (Dry AMD), a serious retinal disease that afflicts millions of patients world- wide and can lead to blindness.
P
VA TePla (TPEG), a German manufacturer of silicon crystallization systems, vacuum and high-
temperature systems, has published its preliminary results for fiscal 2011. The Company generated reve- nues of EUR132.6 million (previous year: EUR120.4 m). The rise in new orders to EUR156.2 million was particularly significant, resulting in correspondingly higher order backlog of currently EUR74.9 million as of December 31, 2011 (2010: orders of EUR93.4 million and order backlog of EUR52.9 million). For fiscal 2012 an EBIT margin of 8 to 10% is anticipa- ted.
http://www.pvatepla.com Q
D Vision, Inc. announced that Professor Ching Tang, inventor of the organic light emitting diode
(OLED) and a winner of the prestigious Wolf Prize in the field of chemistry, has joined the company’s scientific advisory board.
“While Wet AMD, which affects less than 20% of the population with AMD, is well treated with products such as Genentech’s billion dollar Lucentis and/or Regeneron’s Eylea, there currently is no approved treatment for Dry AMD, a disease which affects far more people,” said Dr. Paul Ashton, President and CEO of pSivida. Dr. Ashton added “this is the se- cond tech evaluation agreement pSivida has signed for its bioerodible Durasert technology since pSivida regained the rights to its intellectual property from Pfizer last year.”
http://www.psivida.com
12-02 :: February/March 2012
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89